EGFR and lung adenocarcinoma: In a previous case report, a 65‐year‐old woman with brain metastasis from a lung adenocarcinoma with the EGFR G719X and S768I mutations was treated successfully with osimertinib as the first‐line therapy, demonstrating the efficacy of this drug and its control of central nervous system symptom.15